Rocket Pharmaceuticals, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $29.5M | $31.5M | $29.3M | $34.1M | $42.7M | $35.9M | $37.4M | $42.3M |
| SG&A Expense | $17.4M | $17.1M | $14.7M | $18.4M | $25.0M | $28.4M | $25.3M | $27.1M |
| Operating Income | $-46.9M | $-48.5M | $-44.0M | $-52.2M | $-71.1M | $-64.4M | $-62.7M | $-69.4M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | $473.0K | $473.0K | $473.0K | $473.0K | $473.0K | $472.0K | $473.0K | $471.0K |
| Pretax Income | $131.8M | — | — | — | $-68.9M | — | — | — |
| Income Tax Expense | $8.6M | — | — | — | $0 | — | — | — |
| Net Income | $123.2M | $-47.6M | $-42.5M | $-50.3M | $-68.9M | $-61.3M | $-60.3M | $-66.7M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $1.09 | $-0.42 | $-0.38 | $-0.45 | $-0.62 | $-0.56 | $-0.62 | $-0.71 |
| EPS (Diluted) | $1.08 | $-0.42 | $-0.38 | $-0.45 | $-0.62 | $-0.56 | $-0.62 | $-0.71 |
| Shares Outstanding (Basic) | 112.8M | 112.1M | 111.1M | 111.6M | 111.0M | 110.1M | 94.8M | 94.2M |
| Shares Outstanding (Diluted) | 114.5M | 112.1M | 111.1M | 111.6M | 111.0M | 110.1M | 94.8M | 94.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |